Daniel A. Kietz is engaged in various collaborative, industry-sponsored, clinical translation projects on pediatric rheumatic diseases pertaining to the longitudinal perspective of disease courses, treatment responses, and outcomes. He is PI of a phase IV study on safety and efficacy of abatacept in juvenile idiopathic arthritis, a prevalent autoimmune disease of childhood for which the underlying immune mechanisms are not well understood. He is also co-investigator on a project examining the basic immunology of juvenile idiopathic arthritis.
Kietz is interested in transition of pediatric/adolescent patients into adulthood. Given his qualification as rheumatologist for children and adults, he can continue providing care to his patients after they reach adulthood. Kietz has interest in investigating the influence of this continuity of care with comprehensive anticipatory guidance on long-term outcomes (medical, social, professional, and quality of life).
Professional Affiliations/Society Memberships
- American Academy of Pediatrics
- American College of Rheumatology
- American Psychoanalytic Association
- Southeastern Child Analytic Consortium